BIOPHARMA
By
PhaseV Reports Breakthrough Year in 2025, Marking Transition to Scaled AI Deployment in Clinical Development
Boston, Massachusetts PhaseV announced today that 2025 marked a defining year for the company, highlighted by record revenue…
Takeda Announces Positive Phase III Results for AI-Discovered Oral Psoriasis Therapy
Tokyo, Japan – December 19, 2025 – Takeda Pharmaceutical Company Limited today announced successful results from two Phase…
Cradle AI-powered protein engineering platform serving six of the top 25 global pharma leaders
AMSTERDAM and ZURICH, Dec. 16, 2025 — Cradle, an enterprise-grade AI software platform for protein engineering, today announced…
Adaptive Biotechnologies and Pfizer Announce Strategic Research Collaboration Valued Up to $890 Million to Advance Breakthrough Therapies for Rheumatoid Arthritis and Immune-Mediated Diseases
A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis. A data licensing agreement to…
Will Novo Nordisk Pull Ahead of Eli Lilly with FDA Approval of Oral Wegovy?
The U.S. Food and Drug Administration (FDA) has approved the first daily oral version of the obesity drug…
Is Tanya Alcorn Poised to Transform Pfizer’s Global Hospital and Biosimilars Strategy?
Pfizer has appointed Tanya Alcorn as President, Global Hospital and Biosimilars, expanding her leadership responsibilities after serving more…
